Immunic (IMUX) Competitors $0.91 +0.06 (+7.55%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$0.91 0.00 (-0.20%) As of 05:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX vs. RCKT, TVRD, FDMT, CTMX, ENGN, KRRO, RAPT, ANNX, CTNM, and ALECShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Rocket Pharmaceuticals (RCKT), Tvardi Therapeutics (TVRD), 4D Molecular Therapeutics (FDMT), CytomX Therapeutics (CTMX), enGene (ENGN), Korro Bio (KRRO), Rapt Therapeutics (RAPT), Annexon (ANNX), Contineum Therapeutics (CTNM), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Its Competitors Rocket Pharmaceuticals Tvardi Therapeutics 4D Molecular Therapeutics CytomX Therapeutics enGene Korro Bio Rapt Therapeutics Annexon Contineum Therapeutics Alector Rocket Pharmaceuticals (NASDAQ:RCKT) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership. Do institutionals and insiders believe in RCKT or IMUX? 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 24.8% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Immunic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher earnings & valuation, RCKT or IMUX? Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$258.75M-$2.51-1.27ImmunicN/AN/A-$100.51M-$0.94-0.97 Is RCKT or IMUX more profitable? Rocket Pharmaceuticals' return on equity of -65.11% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -65.11% -55.99% Immunic N/A -461.46%-217.16% Which has more volatility & risk, RCKT or IMUX? Rocket Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Do analysts prefer RCKT or IMUX? Rocket Pharmaceuticals presently has a consensus target price of $16.73, indicating a potential upside of 426.21%. Immunic has a consensus target price of $8.33, indicating a potential upside of 816.96%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Rocket Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 1 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.41Immunic 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to RCKT or IMUX? In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Immunic. MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 1 mentions for Immunic. Immunic's average media sentiment score of 1.84 beat Rocket Pharmaceuticals' score of 1.29 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryImmunic beats Rocket Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.36M$3.16B$5.79B$10.46BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-0.9721.03348.6826.86Price / SalesN/A447.99558.99125.65Price / CashN/A44.8326.0131.15Price / Book4.549.8316.256.50Net Income-$100.51M-$52.82M$3.29B$271.25M7 Day Performance11.51%3.07%200.43%3.27%1 Month Performance-4.34%5.37%184.34%8.15%1 Year Performance-43.20%16.89%334.72%26.51% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.0502 of 5 stars$0.91+7.6%$8.33+817.0%-50.3%$83.36MN/A-0.9770Positive NewsGap UpRCKTRocket Pharmaceuticals4.8015 of 5 stars$3.22+5.0%$16.73+419.2%-84.2%$345.83MN/A-1.28240Positive NewsTVRDTvardi Therapeutics1.7572 of 5 stars$36.63-4.2%$64.25+75.4%N/A$343.48MN/A0.0080News CoverageFDMT4D Molecular Therapeutics2.4767 of 5 stars$7.30+10.6%$30.40+316.4%-37.8%$339.04M$40K-2.06120Positive NewsCTMXCytomX Therapeutics4.2083 of 5 stars$2.06+3.8%$5.42+163.6%+73.1%$338.90M$141.10M3.67170News CoverageAnalyst ForecastENGNenGene2.6031 of 5 stars$6.62-2.9%$21.00+217.0%-5.5%$338.26MN/A-3.4831KRROKorro Bio1.6305 of 5 stars$35.54-1.4%$86.83+144.3%-5.8%$335.78M$6.28M-3.6770RAPTRapt Therapeutics3.5985 of 5 stars$20.17+1.6%$21.57+6.9%+40.6%$333.99MN/A-1.4380Positive NewsGap DownANNXAnnexon1.5219 of 5 stars$3.02+5.4%$12.50+314.6%-57.6%$331.31MN/A-2.3460CTNMContineum Therapeutics2.5752 of 5 stars$11.62-7.1%$22.75+95.9%-43.2%$325.69M$50M-5.2831Positive NewsALECAlector3.787 of 5 stars$3.19+5.1%$4.17+30.8%-44.7%$321.35M$81.13M-2.74270News CoveragePositive News Related Companies and Tools Related Companies Rocket Pharmaceuticals Alternatives Tvardi Therapeutics Alternatives 4D Molecular Therapeutics Alternatives CytomX Therapeutics Alternatives enGene Alternatives Korro Bio Alternatives Rapt Therapeutics Alternatives Annexon Alternatives Contineum Therapeutics Alternatives Alector Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMUX) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMUX Stock Alerts